Akadeum Life Sciences, a global leader in buoyancy-based cell separation and activation technology, is announcing the launch of a new series of products for cell therapy research and development—enabling direct leukopak human immune cell isolation and T-cell activation/expansion kits at the American Society of Gene + Cell Therapy’s 26th Annual Meeting from May 16-20, 2023 in Los Angeles, California. The new products expand Akadeum’s lineup of Buoyancy-Activated Cell Sorting (BACS™) Microbubble buoyancy-based cell isolation kits, enabling the direct isolation of T cells (leveraging GMP-grade kit reagents) and peripheral blood mononuclear cells (PBMCs) from leukapheresis material without the need for lysis or density gradient centrifugation.
This innovative advancement will give immunotherapy researchers the ability to produce high-yield, purified PBMCs and T cells in just one hour while remaining gentle on fragile immune cells.
“The leukopak compatible products added to the BACS™ Microbubble platform emphasizes our commitment to continually grow our offerings into the areas where researchers—and the patients they serve—need them most,” says Brandon McNaughton, PhD, CEO of Akadeum. “Our hope is that by replacing pre-processing with a more gentle, efficient GMP-grade product, researchers will save time while maintaining a foundation of reliable and reproducible results.”
Read more here.